Cargando…

Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis

BACKGROUND: In the RESTORE-IMI 2 trial, imipenem/cilastatin/relebactam (IMI/REL) was noninferior to piperacillin/tazobactam in treating hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. This post hoc analysis was conducted to determine independent predictors of efficac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martin-Loeches, Ignacio, Shorr, Andrew F, Kollef, Marin H, Du, Jiejun, Losada, Maria C, Paschke, Amanda, DeRyke, C Andrew, Wong, Michael, Jensen, Erin H, Chen, Luke F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297016/ https://www.ncbi.nlm.nih.gov/pubmed/37383243 http://dx.doi.org/10.1093/ofid/ofad225

Ejemplares similares

1574. Multivariate Regression Analysis to Determine Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Trial
por: Tipping, Robert, et al.
Publicado: (2020)

1460. Imipenem/Cilastatin (IMI)/Relebactam (REL) in Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia (HABP/VABP): Subgroup Analyses of Critically Ill Patients in the RESTORE-IMI 2 Trial
por: Chen, Luke F, et al.
Publicado: (2020)

1080. Relebactam Increases Imipenem Activity Against Imipenem-Nonsusceptible and -Susceptible Pseudomonas aeruginosa and Enterobacterales: Assessment of Isolates from RESTORE-IMI 2
por: Hilbert, David W, et al.
Publicado: (2021)

1230. Clinical and Microbiologic Outcomes by Causative Pathogen in Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Treated with Imipenem/Cilastatin (IMI)/Relebactam (REL) Versus Piperacillin/Tazobactam (PIP/TAZ)
por: Losada, Maria C, et al.
Publicado: (2020)

Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study
por: Brown, Michelle L, et al.
Publicado: (2020)

Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance
por: Roberts, Jason A, et al.
Publicado: (2023)

Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards—SMART United States 2017–2019
por: Lob, Sibylle H, et al.
Publicado: (2021)

Carbapenem-Nonsusceptible Gram-Negative Pathogens in ICU and Non-ICU Settings in US Hospitals in 2017: A Multicenter Study
por: McCann, Eilish, et al.
Publicado: (2018)

1339. Results for the Supplemental Microbiological Modified Intent-to-Treat (SmMITT) Population of the RESTORE-IMI 1 Trial of Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients with Imipenem-Nonsusceptible (NS) Bacterial Infections
por: Kaye, Keith, et al.
Publicado: (2018)

Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial
por: Martin-Loeches, Ignacio, et al.
Publicado: (2023)

Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018–2020
por: Hilbert, David W., et al.
Publicado: (2023)

A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)
por: Titov, Ivan, et al.
Publicado: (2020)

Growth and Geographic Variation in Hospitalizations with Resistant Infections, United States, 2000–2005
por: Zilberberg, Marya D., et al.
Publicado: (2008)

Increase in Adult Clostridium difficile–related Hospitalizations and Case-Fatality Rate, United States, 2000–2005
por: Zilberberg, Marya D., et al.
Publicado: (2008)

1951. Nephrotoxicity Associated With Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients With Imipenem-Nonsusceptible (NS) Bacterial Infections
por: Brown, Michelle, et al.
Publicado: (2018)

Descriptive Epidemiology and Outcomes of Hospitalizations With Complicated Urinary Tract Infections in the United States, 2018
por: Zilberberg, Marya D, et al.
Publicado: (2022)

Predictors of hospital mortality among septic ICU patients with Acinetobacter spp.bacteremia: a cohort study
por: Shorr, Andrew F, et al.
Publicado: (2014)

Outcomes associated with bacteremia in the setting of methicillin-resistant Staphylococcus aureus pneumonia: a retrospective cohort study
por: Shorr, Andrew F., et al.
Publicado: (2015)

Viruses are prevalent in non-ventilated hospital-acquired pneumonia
por: Shorr, Andrew F., et al.
Publicado: (2017)

Carbapenem Treatment and Outcomes Among Patients With Culture-Positive Complicated Intra-abdominal Infections in US Hospitals: A Retrospective Cohort Study
por: Zilberberg, Marya D, et al.
Publicado: (2019)

718 Predictors of Hospital Mortality Among Septic ICU Patients With Acinetobacter spp. Bacteremia: A Cohort Study
por: Shorr, Andrew F., et al.
Publicado: (2014)

1658 C. difficile Recurrence is a Strong Predictor of 30-day Rehospitalization Among ICU Patients
por: Zilberberg, Marya D., et al.
Publicado: (2014)

Infectious Diseases Consultation Reduces 30-Day and 1-Year All-Cause Mortality for Multidrug-Resistant Organism Infections
por: Burnham, Jason P, et al.
Publicado: (2018)

1450. Frequency of Carbapenem-resistant Pseudomonas aeruginosa Among Respiratory Pathogens Impacts First-Line Beta-Lactam Susceptibility: Potential Role for Ceftolozane/Tazobactam (C/T) and/or Imipenem/Relebactam (I/R)
por: Klinker, Kenneth, et al.
Publicado: (2020)

Assessment of Antibiotic De-escalation by Spectrum Score in Patients With Nosocomial Pneumonia: A Single-Center, Retrospective Cohort Study
por: Ilges, Dan, et al.
Publicado: (2021)

103. Empiric Antibiotic Susceptibility Using a Traditional vs. Syndromic Antibiogram-Implications for Antimicrobial Stewardship Programs
por: Klinker, Kenneth, et al.
Publicado: (2020)

Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study
por: Zilberberg, Marya D, et al.
Publicado: (2014)

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
por: Motsch, Johann, et al.
Publicado: (2020)

Candidemia on presentation to the hospital: development and validation of a risk score
por: Shorr, Andrew F, et al.
Publicado: (2009)

Azithromycin and survival in Streptococcus pneumoniae pneumonia: a retrospective study
por: Shorr, Andrew F, et al.
Publicado: (2013)

Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study
por: Zilberberg, Marya D, et al.
Publicado: (2010)

Development and Validation of a Multivariable Prediction Model for Missed HIV Health Care Provider Visits in a Large US Clinical Cohort
por: Pettit, April C, et al.
Publicado: (2021)

IMI 2021 Yearly Digest
por: Jong, Monica, et al.
Publicado: (2021)

A risk score for identifying methicillin-resistant Staphylococcus aureus in patients presenting to the hospital with pneumonia
por: Shorr, Andrew F, et al.
Publicado: (2013)

151. Simplifying Empiric Antimicrobial Therapy Selection for Lower Respiratory Tract Infections in Intensive Care Unit Patients: Using Resistance Frequency to Guide Decision Making
por: Klinker, Kenneth, et al.
Publicado: (2021)

127. Living on the Edge: The Impact of MIC Distributions on Empiric Antibiotic Selection
por: Bauer, Karri A, et al.
Publicado: (2021)

Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia
por: Shorr, Andrew F, et al.
Publicado: (2006)

IMI Risk Factors for Myopia
por: Morgan, Ian G., et al.
Publicado: (2021)

IMI Impact of Myopia
por: Sankaridurg, Padmaja, et al.
Publicado: (2021)

IMI Pathologic Myopia
por: Ohno-Matsui, Kyoko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1hbnpqh3dntajpm1ihh67luidn